We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

May 5, 2022

Five Expert Insights from the HealthXL Community

Commentary
HealthXL Team & HealthXL Community
&

Over the past month, our HealthXL community members discussed evidence generation strategies for digital therapeutics (DTx), clinical and economic evidence for standalone DTx and non-prescription DTx (non-PDT) patient engagement, among other topics. We’ve put together a snapshot of five expert insights from these meetings.

#1 On evidence generation strategies for DTx: The evidence requirements change depending on the route to market you want to pursue. For example, pharma requirements are not the same as payers. It is critical to know this up front to build the right evidence generation strategy. Tracking safety in the long-term makes a lot of sense for drugs. However, for most DTx products, proving long-term efficacy becomes more important. Even when the product changes to cover new indications, it may not be necessary to focus on safety if it has already been shown for other indications. Safety evidence requirements should be specific to the product and/or disease. 

#2 On the comparison of standalone DTx to drugs or standard treatments: Standalone DTx are not comparable to drugs or standard treatment protocols. They are high-quality software systems that are designed to help treat various medical conditions. However, since DTx intervene in the care regimen of a patient and play a substantive role in the therapeutic process, in many countries they are required to meet the same gold standard of clinical and economic evidence as traditional medical treatments through Randomized Clinical Trials (RCT). As they are technology-based solutions, there are challenges in showcasing clinical and economic evidence. We polled experts from our community for their views on comparing standalone DTx to the standard of care.

#3 On leveraging Digital Health to address comorbidities in oncology: An oncology diagnosis represents a huge shift for a patient. This, along with the treatment, can lead to or exacerbate comorbidities that need to be addressed, such as mental health issues and pain. While digital solutions can help ease that burden in several ways, there needs to be a balance to ensure that they are integrated into a care plan gently, rather than adding additional complexity to an already difficult situation. For providers, this means considering how they can seamlessly integrate into a patient's broader care plan. A more open approach to integration and broad-based care could give clinicians more options to recommend to patients without adding any undue burden to either patient or doctor.

#4 On patient engagement with non-prescription DTx products: Personalization is key when scaling a non-prescription DTx product (non-PDT); this is delivering an experience adapted to each patient's needs and giving them the right therapy at the right time. The use of Artificial Intelligence (AI) and Machine Learning (ML) can help gather patient data and use it for a more personalized experience across the patient journey. One of the biggest challenges when going direct to consumer (D2C) is converting patients from acute therapy to maintenance; as soon as they have no symptoms they stop using it. Especially those patients referred from insurance, which only paid for the acute therapy. 

#5 On HCP and Patient adoption of DTx in Neurology: Most neurological patients see their physician only once or twice a year. In-between visits, self-care becomes really important. Tools that support this self-care may have more success with patient engagement. However, patients need to be involved in the product development process. There are currently a lot of apps for neurology patients that have accessibility problems (i.e. tiny buttons). For healthcare professionals (HCPs) it’s important that solutions only give physicians the minimum essential actionable information. Too much data can become a burden. 

Want to join the conversation? Check out our website for upcoming meetings and events. 

Interested in more expert insights and takeaways? Become a member of our HealthXL Community for access to polls and summaries from all of our meetings.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Standing Out from the Crowd in Economic Recession

14th February @ 10:45AM EDT

The digital health industry has seen a decline in funding in recent times, as investors have become more knowledgeable and selective to where they allocate their capital. Seats are limited so apply now to secure your place.

Featuring
Jeremy Sohn
Jeremy Sohn
Managing General Partner, P74 Ventures
Featuring
Jeremy Sohn
Jeremy Sohn
Managing General Partner, P74 Ventures
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Endpoints and Control Arms in Trials for DTx

15th February @ 10:45AM EDT

Proving clinical efficacy is one of the biggest challenges for DTx companies. Apply now to join HealthXL in this session to dive deeper into this topic with leaders in this field.

Featuring
Acacia Parks
Acacia Parks
Chief Science Officer, Twill
Featuring
Acacia Parks
Acacia Parks
Chief Science Officer, Twill
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

The Role of the Consumer Experience in DTx

15th February @ 10:45AM EDT

As technology advances in all sectors (e.g. fintech, entertainment, etc), consumer behaviour changes and the expectations on user experience are higher than before. Apply now to secure your place in this meeting where you will dive deeper into this topic with your peers.

Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wireVentures
Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wireVentures
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Incorporating Extended Reality (XR) in Physician's’ Daily Work

28th February @ 10:45AM EDT

The healthcare industry is undergoing a digital transformation and extended reality (XR) technologies such as virtual reality (VR) and augmented reality (AR) are expected to play a significant role in this change in the next few years. Apply now to join this Masterclass led by Nemanja Kovačev, MedTech Expert at HTEC Group.

Featuring
Nemanja Kovačev
Nemanja Kovačev
MedTech Expert, HTEC Group
Featuring
Nemanja Kovačev
Nemanja Kovačev
MedTech Expert, HTEC Group

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Health Meeting
7th February @ 10:45AM EDT

Product Differentiation for Digital Health Solutions in the Cardiometabolic Disease Area

In the past few years, digital health solutions have proven to be helpful in preventing and managing cardiometabolic diseases remotely, leading to better  health outcomes and less hospitalizations, emergency visits, and in-office visits.

Jenn Roberts
Featuring
Jenn Roberts
Vice President Employer Health Strategy, Hello Heart
Telemedicine & Virtual Care Delivery
8th February @ 10:45AM EDT

Why is now a good time for Digital Health-MedTech Partnerships?

There have been many failed partnerships between pharma and digital health companies, and most ongoing projects are struggling to make it work out. Join this meeting to discuss this topic further with your peers. Places are limited so apply now to secure your place.

Matt Norton
Featuring
Matt Norton
Vice President of Marketing & Commercial Development at S3 Connected Health
Telemedicine & Virtual Care Delivery
9th February @ 10:45AM EDT

Business Opportunities for Digital Health in Autoimmune Conditions: Upcoming Blockbuster Drugs

Millions of people worldwide suffer from autoimmune conditions such as rheumatoid arthritis (RA), psoriasis, lupus, Crohn's disease, multiple sclerosis, atopic dermatitis, to name a few. Join this meeting to deep dive into this topic in the Immunology Meeting Series. Seats are limited so apply now to secure your place.

Erik Janssen
Featuring
Erik Janssen
VP Global Digital Care Transformation Immunology, UCB
Digital Therapeutics (DTx)
14th February @ 10:45AM EDT

Masterclass: Standing Out from the Crowd in Economic Recession

The digital health industry has seen a decline in funding in recent times, as investors have become more knowledgeable and selective to where they allocate their capital. Seats are limited so apply now to secure your place.

Jeremy Sohn
Featuring
Jeremy Sohn
Managing General Partner, P74 Ventures

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.